Loading...
XSHG600645
Market cap1.20bUSD
Jan 14, Last price  
19.33CNY
1D
3.92%
1Q
-4.78%
Name

Zhongyuan Union Cell & Gene Eng Corp Ltd

Chart & Performance

D1W1MN
XSHG:600645 chart
P/E
82.64
P/S
5.53
EPS
0.23
Div Yield, %
0.00%
Shrs. gr., 5y
3.22%
Rev. gr., 5y
3.78%
Revenues
1.59b
+2.24%
281,256,153354,367,347407,355,448392,188,205288,105,421307,749,244268,473,344246,737,638300,342,739361,309,762476,864,594708,994,855837,900,550870,913,4971,320,517,6771,386,778,8481,318,893,8561,535,328,6531,554,886,9431,589,723,333
Net income
106m
-5.78%
007,975,62511,875,29739,097,7702,124,8718,380,45123,426,18813,898,9007,215,73335,464,991208,353,11337,859,920059,252,90449,694,8010155,320,080112,986,649106,452,669
CFO
299m
+14.18%
57,761,45384,686,47976,115,125111,679,834121,602,969124,917,732175,925,959110,444,59370,409,955110,722,693221,454,6968,174,936143,667,30870,269,191130,081,956241,490,023244,354,437320,957,061261,890,840299,015,343
Dividend
Aug 10, 20010.016 CNY/sh
Earnings
May 20, 2025

Profile

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell tests in the People's Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. It also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, safe medication guide gene testing for children and adults, disease genetic testing, disease susceptibility gene testing, etc.; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products. In addition, the company is involved in the research, development, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and experimental synthetic agents; and in vitro diagnostic reagents and medical devices. Vcanbio Cell & Gene Engineering Corp., Ltd was founded in 1992 and is based in Tianjin, the People's Republic of China.
URL
http://www.vcanbio.com
IPO date
May 04, 1993
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,589,723
2.24%
1,554,887
1.27%
Cost of revenue
1,149,957
1,139,340
Unusual Expense (Income)
NOPBT
439,767
415,547
NOPBT Margin
27.66%
26.73%
Operating Taxes
34,035
48,525
Tax Rate
7.74%
11.68%
NOPAT
405,732
367,022
Net income
106,453
-5.78%
112,987
-27.26%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
29,647
27,503
Long-term debt
162,998
188,379
Deferred revenue
10,025
10,925
Other long-term liabilities
21,625
11,600
Net debt
(2,168,564)
(2,300,014)
Cash flow
Cash from operating activities
299,015
261,891
CAPEX
(88,615)
Cash from investing activities
(90,492)
Cash from financing activities
(18,726)
FCF
465,938
367,569
Balance
Cash
1,581,245
1,393,432
Long term investments
779,963
1,122,464
Excess cash
2,281,723
2,438,152
Stockholders' equity
423,224
699,105
Invested Capital
3,512,889
3,052,130
ROIC
12.36%
12.35%
ROCE
11.11%
10.98%
EV
Common stock shares outstanding
462,838
467,949
Price
20.27
19.17%
17.01
-32.61%
Market cap
9,381,720
17.86%
7,959,811
-32.61%
EV
7,327,705
5,757,648
EBITDA
600,906
553,754
EV/EBITDA
12.19
10.40
Interest
11
1,269
Interest/NOPBT
0.00%
0.31%